Podcasts about oehler

durée : 00:06:29 - Le Bach du matin du lundi 24 février 2025 - Notre Bach du matin est un Bach orchestré ! Le compositeur Thomas Oehler propose une orchestration de ma deuxième partita pour claviers du compositeur, ici interprétée par les solistes de l'Académie Royale de Musique de Londres dirigé par Trevor Pinnock

durée : 00:06:29 - Le Bach du matin du lundi 24 février 2025 - Notre Bach du matin est un Bach orchestré ! Le compositeur Thomas Oehler propose une orchestration de ma deuxième partita pour claviers du compositeur, ici interprétée par les solistes de l'Académie Royale de Musique de Londres dirigé par Trevor Pinnock

Kathryn and Michael, co-hosts of the 'Building Bigger Lives' podcast, welcomed Amy Oehler from Cornerstone Mortgage to discuss her journey in the mortgage industry and her vision for the future. Amy shared her journey in the mortgage industry, starting as a young person in a file room and progressing through various roles, eventually finding fulfillment as an originator. She discussed her transition to a high-volume team, where she found the concept of team coverage and "turning off" work exciting. They also emphasized the importance of thinking big, collaboration, and perseverance in the industry, with Amy sharing her personal transformation story and the impact of her actions on others.  Building Bigger Lives Podcast- https://www.instagram.com/buildingbiggerlives Contact Coach Michael Regan- www.facebook.com/CoachMichaelRegan www.instagram.com/coachmichaelregan/ www.linkedin.com/in/mregan/ Contact Kathryn Pedersen- http://www.instagram.com/steamboatmortgage  

Dr. Richard L. Oehler, Professor of Medicine at the Division of Infectious Diseases, Morsani College of Medicine, reviews two important clinical syndromes caused by Spirochetes. Dr Oehler begins by presenting an actual clinical case of Leptospirosis in a returning traveller from the Caribbean. He then discusses the epidemiology of Leptospira, a widespread zoonotic pathogen that favors temperate and topical climates worldwide. He then relates the life cycle, means of transmission, microbiology, clinical manifestations, and most relevant diagnostic studies. He concludes the leptospirosis section by discussing treatment and prevention. The second case he discusses is a febrile illness in a returning traveler from Jordan. Dr. Oehler goes on to discuss the epidemiology and classification system for relapsing fever (RF), and its broad categorization into tick-borne (endemic) and louse-borne (epidemic) forms. He further describes the characteristics of the soft-shelled Ornithodoros ticks and the Human Body Louse, and differentiates the Hard Tick Relapsing Fevers such as Borellia miyamotoi and B. lonestarii. He then reviews the clinical manifestations, diagnostic criteria, and treatment options for each form of RF. Lastly, Dr, Oehler breaks down treatment and prevention strategies for each form of relapsing fever.

HEUTE bringt Daniel Weinstock wieder einen spannenden Gast mit: Lisa Oehler berichtet von ihren einzigartigen Erfahrungen mit der INSTANT CHANGE Methode. Du möchtest mehr über die INSTANT CHANGE Methode erfahren? Dann melde Dich jetzt zum kostenfreien Online Training an:https://instant-change.com/icm/ictraining/?source_id=2254

Dr. Richard Oehler, Professor of Medicine at the Division of Infectious Diseases at the University of South Florida Morsani College of Medicine, presents a review of bacteremia. Dr. Oehler begins by reviewing the epidemiology, personal and institutional costs of bacteremia. He then discusses blood culture collection and how false positive blood cultures occur. With the recent blood culture bottle shortage of 2024, he emphasizes the new concept of “blood culture stewardship”–when it is most appropriate to order a blood culture versus when it may be unnecessary. Next, Dr. Oehler reviews automated blood culture systems and other related identification technology, with a focus on new methods of blood culture isolate identification such as multiplex PCR and Maldi-TOF. The speaker then contrasts gram positive and gram negative bacteremia in general and by organism. The management of a positive blood culture with regard to treatment and source control is discussed. Lastly, ways to reduce the incidence of bacteremia are shared.

In dieser Podcast-Episode gehen wir der Frage nach, ob mit künstlicher Intelligenz ein Quantensprung in Planung und Analyse bevorsteht. Gemeinsam mit Prof. Dr. Karsten Oehler, Chief Solution Advisor bei SAP Deutschland, erkunden wir zunächst die Potenziale von KI in den Bereichen Reporting und Analyse, insbesondere die Chancen im Self-Service. Darüber hinaus diskutieren wir die Auswirkungen auf Planungsprozesse und beleuchten, wie eine neue und sinnvolle Arbeitsteilung zwischen Mensch und Maschine gestaltet werden kann. Die Episode bietet wertvolle Einblicke in die transformative Kraft von KI in Planung und Analyse und zeigt, wie Unternehmen von diesen Entwicklungen profitieren können.

Episode No. 664 features curator Sarah Kelly Oehler and artist Rebecca Manson. With Annelise K. Madsen, Oehler is the co-curator of "Georgia O'Keeffe: “My New Yorks." The exhibition spotlights O'Keeffe's paintings of New York City, surrounding them with pictures she made of Lake George and the Southwest. It's at the Art Institute of Chicago through September 22, when it will travel to the High Museum of Art in Atlanta. The exhibition catalogue was published by the AIC. Amazon and Bookshop offer it for $40-46. The Modern Art Museum of Fort Worth is showing "Rebecca Manson: Barbecue," an immersive installation made from ceramic. Manson's work has been shown in group shows at institutions such as Ballroom Marfa in Texas, and the Center for Craft, Asheville, NC, and at Tribeca Park in New York. "Manson" was curated by Clare Milliken and will be on view through August 25. Instagram: Sarah Kelly Oehler, Rebecca Manson, Tyler Green.

I'm delighted to speak with Elisabeth Oehler this week. Elisabeth is a Sports Performance and Strength and Conditioning Coach.  Elisabeth has worked in various sports in multiple countries and is currently Strength and Conditioning Coach for the Saudi Olympic Training Center. Elisabeth has her own consultancy practice EO Performance. Previously, Elisabeth was the Strength and Conditioning Coach for DHL Stormers Western Province Rugby in South Africa. Elisabeth takes a holistic approach to athlete development in her coaching to make her athletes stronger, faster, and more powerful. Besides the physical performance aspects, she helps her athletes to develop mental toughness, integrity, the ability to work in a team, discipline, respect, and leadership skills on and off the field or competition floor. Elisabeth is currently undertaking a Professional Doctorate in Elite Performance at Dublin City University.

This week's episode I talk with Andrew about what kind of wacky things we'd like to see in X-Wing in the future. Join me on ⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠ for early access videos Saturdays at 9pm EST.

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

The validation of TKIs as a treatment for patients with chronic myeloid leukemia (CML) began the revolution in care for this previously hard-to-treat malignancy, but the fight for even better outcomes continues. Continued innovation in the form of second- and third-generation TKIs and STAMP inhibitors has established a new era of potent and effective options across CML treatment settings and patient populations—but are you prepared for what's next? In this activity, based on a recent live symposium, an expert panel provides foundational evidence supporting new targeted therapy management models in a variety of CML settings (eg, newly diagnosed disease, TKI treatment resistance) and use case-based discussion on the integration of newer TKIs, STAMP inhibitors, and potentially innovative combination regimens into clinical practice. Throughout, the experts highlight practical tools to capture loss of response and resistance mutations and address dosing, toxicity, and adherence considerations. Don't miss the ‘sequel' to the TKI era in CML! Upon completion of this activity, participants should be better able to: Summarize current practice recommendations and safety/efficacy evidence supporting the use of innovative targeted strategies, including treatment with TKIs or novel STAMP inhibitors, across multiple lines of therapy and CML treatment settings; Utilize recommended monitoring strategies to identify clinically relevant features to inform treatment decisions along the continuum of CML disease; Develop customized treatment plans that incorporate validated TKI and STAMP inhibitor approaches based on current evidence, disease features, safety considerations, and patient preferences; and Manage the suite of practical considerations, including dosing, monitoring, adherence, and AEs (eg, cardiovascular complications, rash, fluid retention), associated with using novel targeted strategies

Dr. Richard Oehler, Professor of Medicine at the Division of Infectious Diseases and International Medicine, Morsani College of Medicine at USF, presents this overview of Nocardia and Actinomyces, two closely-related gram positive filamentous rods which have distinct differences. In his presentation, Dr. Oehler initially covers Nocardiosis, followed by Actinomycosis, and compares and contrasts both and how they produce human infection. Topics covered for both infections include their taxonomy, epidemiology, types of patients infected, infectious syndromes, potential complications, recommended therapies, and duration of treatment. At the end of the talk both Nocardiosis and Actinomycosis are directly compared to help summarize the important learning points presented.

Heute sprechen wir mit dem Webdesigner Robin Oehler. Robin hat einige spannende Standbeine: Er ist mit seiner Firma roehler erfolgreich selbstständig und arbeitet mit vielen mittelständischen Unternehmen zusammen. Nebenbei betreibt er noch eine AI-Bilderagentur, welche sich auch sehen lassen kann. Sein Vergleichsportal LaHUGE, das mit Bitcoin Cashback hätte laufen sollen, konnte sich leider nicht durchsetzen. Aber auch diese Geschichte ist überaus spannend und ihr könnt einige Lehren daraus ziehen, so wie es Robin im Podcast erzählt. Wir sprechen darüber, wie wichtig der Standort im Webdesign ist, über Akquise und auch das Thema Steuern. Wieder einmal eine sehr unternehmerische Folge - hört rein! Website: https://www.roehler.nrw/ LinkedIn: https://www.linkedin.com/in/robinoehler/ Life After SAE auf Instagram: https://www.instagram.com/lifeaftersae/ Mehr zu Kurt gibt's hier: https://www.kurt-jonathan-engert.com Mehr zu Glen gibt's hier: https://glenschaele.com/linktree

“Paddling in the Copenhagen harbor with hundreds of people and looking up at thousands of people lining the shores singing together…”

Un épisode spécial dans lequel on interview le CEO d'Infomaniak, dans le cadre de notre partenariat (rémunéré) avec eux. On a passé un excellent moment et on est fier de pouvoir présenter une telle entreprise suisse! Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Dr. Richard L. Oehler, MD, Professor of Medicine at the USF Morsani College of Medicine, presents this update on Diabetic Foot Infections (DFIs). Focusing on recent guidelines updates from 2023, Dr. Oeher discusses DFI epidemiology, pathophysiology, and Diabetic foot exam basics. He then goes on to review diabetic vascular disease and its role in the progression of diabetic foot complications. Dr. Oehler then reviews the workup of diabetic foot infections including imaging and physical examination findings. Lastly, the management of diabetic foot osteomyelitis is discussed including treatment strategies and prevention.

Avec Jérémie Oehler

Co-hosts Robin Schooling as they chat with Ken Oehler, Senior Partner, Head of People Science, for RADICL.    Ken Oehler,, has a deep understanding of employee experience, and we discuss the role of leadership in creating a great work experience. On the show, we discuss: .RADICL and what they doThe STATE OF THE WORK EXPERIENCE REPORTThe main findings of the reportWhat a RADICL Work Experience is    

Avec Jérémie Oehler

Avec Jérémie Oehler

Infomaniak partage les valeurs de Tech Café : éthique, écologie et respect de la vie privée. Découvrez les services de notre partenaire sur Infomaniak.comMarc Oehler, CEO d'Infomaniak, se confie sur son rapport à la tech, le rôle du dirigeant d'une entreprise, et sur les enjeux de l'hébergement et des services cloud

Episode 251 is with the Strength & Conditioning coach at the Saudi Olympic Training Centre Elisabeth Oehler⁣ ⁣ We discussed:⁣ ▫️The Women's World Cup⁣ ▫️The next steps needed in the women's game⁣ ▫️Ensuring players are ready for 1st team⁣ ▫️Managing players who are called up early⁣ & much more!⁣ ⁣ You can follow Elisabeth on Twitter @eo_performance⁣ ⁣ If you enjoy this episode make sure to check out the previous episodes below:⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Brett Bartholomew - https://youtu.be/W95WIZXl5u0⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Gareth Sandford & Damien Harper - https://youtu.be/BQUYkihCeD8⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Stu McMillan - https://youtu.be/ya5b3TCm9Ws⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Keep up to date with the amazing work our sponsors are doing here:⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Good Prep - https://thegoodprep.com⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Discover the power of nutrition at WWW.THEGOODPREP.COM and use code FFF15 for 15% off your first order⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Rezzil - rezzil.com⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Hytro - hytro.com⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Maximise your athletic potential with Hytro BFR. Easier, safer and more practical BFR for squads to prepare for and recover from exercise than ever before.⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Click the link [[ https://bit.ly/3ILVsbU ]] to speak to our Pro Sports team about how to get Hytro BFR at your club.⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Join our online community & get access to the very best Football Fitness content as well as the ability to connect with Sport Scientists and Strength & Conditioning coaches from around the world.⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ To get FULL access to all of these & even more like this, sign up to a FREE month on our online community at the link below.⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ www.footballfitfed.com/forum/index.aspx⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Keep up to date with everything that is going on at Football Fitness Federation at the following links:⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Twitter - @FootballFitFed⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Instagram - @FootballFitFed⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Website - www.footballfitfed.com⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ Email - mail@footballfitfed.com⁣⁣

Avec Jérémie Oehler

*Änderung - Kim und ich möchten uns von der Band Rammstein distanzieren und das Lied wird nicht in unserer Playlist auftauchen. Von Lampenfieber über Safespace bis hin zu eigenen Emotionen. Auch wenn viel "Hihi" in der Folge war, gab es tiefsinnige Themen und andere Blickwinkel. UNSER GAST: https://www.instagram.com/kimmarao SUPPORTE DEN PODCAST! PATREON LINK: https://www.patreon.com/thewonderworld PLAYLIST WONDERTALK: LEBENSLIEDER FOLGT: THE WONDERWORLD X https://www.instagram.com/wonderworld.community UNSER STUDIO X https://www.instagram.com/wonderworld.studios Sebastian Wunder X https://www.instagram.com/iamwxnder - https://www.thewonderworld.de -

Avec Jérémie Oehler

Hosted by Randy Pettitt Randy sits down with NHRA Pro Stock Motorcyclist Ryan Oehler for an in depth interview on his career and future. The Pit Stop previous episodes available via the Tobacco Road Sports Radio podcast network. --- Support this podcast: https://podcasters.spotify.com/pod/show/tobacco-road-sports-radio/support

Avec Jérémie Oehler

Avec Jérémie Oehler

Avec Jérémie Oehler

Avec Jérémie Oehler

In this episode, I discuss the many medicinal uses of Licorice... and I tell you how to make my soon to be world-famous chili con carne. I discuss underground houses/greenhouses, Rocky Erikson and SKip Spence, the importance of teaching your kids to eat diverse, adult food, green woodworking, axes.. and more!Read about my new book: Medicinal Ferns and Fern Allies, an Herbalist's Guide https://southernappalachianherbs.blogspot.com/2022/11/medicinal-ferns-and-fern-allies.htmlAvailable for purchase on Amazon: https://www.amazon.com/dp/B0BMSZSJPSRead about my new cookbook, The Omnivore's Guide to Home Cooking for Preppers, Homesteaders, Permaculture People and Everyone Else: https://southernappalachianherbs.blogspot.com/2022/10/the-omnivores-guide-to-home-cooking-for.htmlAvailable for purchase on Amazon: https://www.amazon.com/dp/B0BGKX37Q2Visit my Substack and sign up for my free newsletter: https://judsoncarroll.substack.com/Read about my new other book, Medicinal Shrubs and Woody Vines of The American Southeast an Herbalist's Guide https://southernappalachianherbs.blogspot.com/2022/06/medicinal-shrubs-and-woody-vines-of.htmlAvailable for purchase on Amazon https://www.amazon.com/dp/B0B2T4Y5L6 andGrowing Your Survival Herb Garden for Preppers, Homesteaders and Everyone Elsehttps://southernappalachianherbs.blogspot.com/2022/04/growing-your-survival-herb-garden-for.htmlhttps://www.amazon.com/dp/B09X4LYV9RThe Encyclopedia of Medicinal Bitter Herbs: https://southernappalachianherbs.blogspot.com/2022/03/the-encyclopedia-of-bitter-medicina.htmlAvailable for purchase on Amazon: https://www.amazon.com/dp/B0B5MYJ35RandChristian Medicine, History and Practice: https://southernappalachianherbs.blogspot.com/2022/01/christian-herbal-medicine-history-and.htmlAvailable for purchase on Amazon: www.amazon.com/dp/B09P7RNCTBHerbal Medicine for Preppers, Homesteaders and Permaculture People: https://southernappalachianherbs.blogspot.com/2021/10/herbal-medicine-for-preppers.htmlAlso available on Amazon: www.amazon.com/dp/B09HMWXL25Podcast: https://www.spreaker.com/show/southern-appalachian-herbsBlog: https://southernappalachianherbs.blogspot.com/Free Video Lessons: https://rumble.com/c/c-618325

I spoke with Null Device's Eric Oehler and Jill Sheridan. Founded in 1995 in Wisconsin, Null Device is constantly experimenting and evolving their sound, drawing a wide variety of influences, passionately fusing everything from bhangra to post-punk to pop to ambient rock into their music. Null Device is always pushing the borders of synthpop, but what is constant is their soaring, catching melodies, lush vocals and meticulously-crafted production. The band consist of founder Eric Oehler (singer, songwriter, violinist) and Co-founder Eric Goedken (Lyricist and producer), Jill Sheridan (Singer, songwriter and long time contributor) and Kendra Kreutz (Cellist and system engineer ).Null Device released their eight album, "The Emerald Age"by Distortion Productions. The album is available on CD and on all streaming and digital platforms. "The Emerald Age" explodes with synthpop hooks that collide with aggressive Berlin-influenced beats, propulsive body music bass, symphonic orchestration, and moody atmospherics. https://www.nulldevice.comPlaylist and podcast: https://djnocturna.comYouTube:  https://www.youtube.com/c/DJNocturnaListen : http://modsnapradio.comQUEEN OF WANDS with DJ NocturnaEvery Saturday on ModSnap RadioKMOD: San Antonio"San Antonio's leading alternative streaming Radio Station since 2017"2pm (HST), 5pm (PST), 6pm (MST), 7pm (CST), 8pm (EST)#ModsnapRadio #Postpunk #goth #Industrial #Dark80s  #DarkWave #ethereal

In this episode, McIntyre gives us an inside look at his coaching service. We get a fly-on-the-wall point of view as he records a live coaching call with a client, Cole Oehler. Consider this Next Level Access. Enjoy.    You can register for McIntyre's Next Level Life and Next Level Experience by visiting THEMICHAELMCINTYRE.COM   Get your copy of McIntyre latest book, NEXT LEVEL LIFE.   Check out the other shows from KB PODCAST PRODUCTIONS: THE KINGDOM BRINGER PODCAST SUPER-NATURAL LIVING WITH BETH PACKARD  CINDY STEWART PODCAST KINGDOM MASTER MIND PODCAST WITH ANN MCDONALD   Podcast music from HOOKSOUNDS.COM

Avec Jérémie Oehler

Dr. Richard L. Oehler, Professor of Medicine at the Division of Infectious Diseases, Morsani College of Medicine, reviews two important clinical syndromes caused by Spirochetes. Dr Oehler begins by presenting an actual clinical case of Leptospirosis in a returning traveller from the Caribbean. He then discusses the epidemiology of Leptospira, a widespread zoonotic pathogen that favors temperate and topical climates worldwide.He then relates the life cycle, means of transmission, microbiology, clinical manifestations, and most relevant diagnostic studies. He concludes the leptospirosis section by discussing treatment and prevention . The second case he discusses is a febrile illness in a returning traveler from Jordan. Dr. Oehler goes on to discuss the epidemiology and classification system for relapsing fever (RF), and its broad categorization into tick-borne (endemic) and louse-borne (epidemic) forms. He further describes the characteristics of the soft-shelled Ornithodoros ticks and the Human Body Louse. He then relates the clinical manifestations, diagnostic criteria, and treatment options for each form of RF. Lastly, Dr, Oehler breaks down treatment and prevention strategies for each form of relapsing fever.

Avec Jérémie Oehler

This podcast interview focuses on product innovation that has the power to help us spot, hire & develop the right team for our performance culture … by amplifying the people characteristics that make our business remarkable. My guest is Dr. Patrick Oehler, Co-Founder, and Co-CEO of Retorio. Patrick Oehler was born in Munich, Germany. After graduating from high school, he studied information-oriented business administration at the University of Augsburg and Management & Strategy at the London School of Economics (LSE). Subsequently, he completed his doctorate in Organizational Research at the Technical University of Munich, where he researched behavioral patterns in organizations. This is where he and his co-founder and co-CEO Christoph Hohenberger stumbled upon a big idea that would spark the birth of Retorio. Retorio is on a mission to create a world where people feel accepted, satisfied, and fulfilled in their work, relationships, and company culture. How? By spotting success patterns in teams, hiring matching talents, and developing them into top performers. And this inspired me, and hence I invited Patrick to my podcast. We explore what's broken in the way we do recruitment today, particularly in large organizations. Patrick shares how 'simply' changing the order of doing creates a revolution - one that creates unbeatable organizations. He digs into how he created traction by niching down and homing in on the most valuable and critical use case. He shares a fascinating story about how he ignored advice from investors on who to target/ not to target - and with that, found a market that's prepared to pay a premium and now represents 80% of the revenue. Last but not least, he shares his experience on what it takes to create a software business that cannot be ignored. Here's one of his quotes "Our investor told us 'don't sell to these clients because they're way too big, they're way too complicated - don't do enterprise sales. You don't know how to do that. You must go for the small ones, this way you can scale way more quickly.' And we always tried to do that, but then once again, the enterprise clients signed up and they were like, 'We're gonna pay more, and we're gonna pay more.' And they offered us big amounts of money to use the technology. And at some point, we said, okay, maybe we should stop resisting.' During this interview, you will learn four things: How flipping the process can be the key to creating a product that creates a revolutionary impact   How a compelling vision can attract critical resources to your startup that are even prepared to work for free How to break the barriers to getting customers to sign up for demos Why your go to market should be ultra specific, even though your platform can support 100s of use cases For more information about the guest from this week: Dr. Patrick Oehler Website Retorio Subscribe to the Daily Value Inspiration Get my free, 2 min daily reflection on shaping a B2B SaaS business no one can ignore. Subscribe here Learn more about your ad choices. Visit megaphone.fm/adchoices

Avec Jérémie Oehler

Dr. Richard Oehler, Professor of Medicine at the Division of Infectious Diseases at the University of South Florida Morsani College of Medicine, presents a review of bacteremia. Dr. Oehler begins by reviewing the epidemiology, personal and institutional costs of bacteremia. He then discusses blood culture collection and how false positive blood cultures occur. Next, Dr. Oehler reviews automated blood culture systems and other related identification technology. The speaker then contrasts gram positive and gram negative bacteremia in general and by organism. The management of a positive blood culture with regard to treatment and source control is discussed. Lastly, ways to reduce the incidence of bacteremia are related.

This episodes comes to you from our recent customer event at Cherrybend Pheasant Farm near Wilmington, Ohio. We had the opportunity to talk with some of our vendors, including Ryan Oehler from Ag Leader. This company, as its name implies, has been a leader in precision agriculture for decades and has especially stood out among the rest in this volatile year with its supply chain woes. Listen in and hear how the company was started, its approach to technological progress, and their view of the future. Thank you for listening and make sure to check out agleader.com. 

NHRA Pro Mod racers Lyle Barnett and JR Gray join Joe Castello to preview the Amalie Oil NHRA Gatornationals. These small tire grudge racers, turned Pro Mod racers discuss their personal rivalry and 2021 race wins. Flyin Ryan Oehler will give the details of his pre Gainesville event at Hooters and talk about the start of the NHRA Camping World Pro Stock Motorcycle season, and Taylor Chomiski will preview his first race in Competition Eliminator with power originally built by and NHRA Pro Stock legend. #NHRA #DragRacing #Gatornats #Pro Stock #Lyle Barnett #BeerMoney #NHRAinterviews #Nitro #NHRAresults #Gatornationals #JRGray #TaylorChomiski #RyanOehler #ProMod WFO Radio has been podcasting interviews with NHRA Drag Racers for over a decade. Check out our feeds for your favorite NHRA Drag Racing drivers and teams. Questions and comments are appreciated as we break down NHRA results from each Camping World and Lucas Oil Drag Racing Series event. Drivers like John Force, Steve Torrence, and Erica Enders never miss a chance to go WFO after they win a race! Apple: https://apple.co/35Z85Rk Soundcloud: https://soundcloud.com/wforadio Spotify: https://spoti.fi/3uznrGl FREE APP: https://wforadio.com/m/ WFO Merch: https://bit.ly/3HC1dY7 Join the WFO Universe! Our Ignition podcast features a world-wide conversation about the latest in NASCAR, NHRA, F1, and Sports. It's an audio only exclusive! About the host: https://wforadio.com/about/

Arizona radio host Jody Oehler joins Dave Softy Mahler and Dick Fain to talk about the relationship between Kyler Murray and the Cardinals, his statement on social media today, and his future in Arizona.

In this episode I sat down with Matt Oehler again for a part 2 because in the first recording, Matt shared with me the intense experience he had as a young man in New York actually witnessing 911 as it happened. Then, offering aid as a trained Marine reserve attend to the injured and the dead that day, to going full time into the Marines to serve our country in Iraq surviving one of the areas most deadly attacks on his group to now, years later having served our country again as a law enforcement officer putting his life on the line year after year and what we can learn from that. We ran out of time in the first session and part two needed to be heard. As I sat and listened to Matt unfold his story of law enforcement, I realized even more clearly that he is a good man, a husband, father, and son. He loves to serve others. He would do anything to help another in trouble. And we sit back and hear judgement against these good men and women to serve and this behind the scene needed to be heard by not only me but anyone out there wanting to know some truth about these heroic people! Matt had many close calls with death in these years of Laws enforcement and he saw death take place all around him for years. That changes ones perspective on life and how precious it is. Matt gets that! Thanks again Matt for your devoted service to all of us. --- Send in a voice message: https://anchor.fm/bob-howard9/message

When a retired librarian in Oregon started corresponding with a man in a Louisiana prison, neither of them could have imagined it would lead to his release and exoneration. Yutico Briley was sentenced to 60 years without parole at the age of 19 for an armed robbery he didn't commit. He wrote to journalist and author Emily Bazelon, pleading with her to cover his case and the many injustices that lead to his conviction. His letter remained unread until Briley's longtime penpal, Karen Oehler, emailed Bazelon and urged her to look at it. Bazelon chronicled the years-long struggle that followed in a recent New York Times Magazine article. After he was released in March, Briley visited Oehler in Oregon. We hear from Briley and Oehler about how their ongoing friendship has affected both of their lives.